Spark Therapeutics Initiates Phase 1/2 Clinical Trial of SPK-CHM for Choroideremia, Expanding its Pipeline of Potential Treatments for Rare, Blinding Conditions.
In: PR Newswire, 2015-01-20
Zeitungsartikel
Zugriff:
Titel: |
Spark Therapeutics Initiates Phase 1/2 Clinical Trial of SPK-CHM for Choroideremia, Expanding its Pipeline of Potential Treatments for Rare, Blinding Conditions.
|
---|---|
Zeitschrift: | PR Newswire, 2015-01-20 |
Veröffentlichung: | 2015 |
Medientyp: | Zeitungsartikel |
Sonstiges: |
|